Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Product › Details

olaptesed pegol (NOX-A12)

Products Next higher product group Spiegelmer® product
Period Status 2009-11-02 development p1 start
Organisation Organisation Noxxon Pharma AG
  Indication      

Noxxon Pharma AG. (11/2/09). "Press Release: Noxxon Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12". Berlin.

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

The Phase I program is currently being conducted in Germany following review and approval of the Clinical Trial Application by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). This single center study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 42 individuals, following intravenous administration of the hematopoietic stem cell (HSC) mobilizing Spiegelmer® NOX-A12. Further information about this clinical trial is available on www.clinicaltrials.gov (ID: NCT00976378).

Dr. Frank Morich, Chief Executive Officer of NOXXON, commented: “Based on exceptionally positive pre-clinical data, we strongly believe that, NOX-A12 has the potential to become an improved alternative for hematopoietic stem cell mobilization. Our goal is to have NOX-A12 approved by 2014. In this ongoing trial we are expecting to see a good safety profile and to gain
initial efficacy data that will further validate the value of the Spiegelmer® technology for the drug development in areas with high unmet medical need.”

NOX-A12 binds and neutralizes the chemokine Stromal Cell-Derived Factor-1 (SDF-1, also known as CXCL12), a key regulatory element in the homing and retention of HSCs in the bone marrow. Mobilized HSCs can be collected by leukapheresis, a process that is generally preferred to invasive bone marrow harvesting. NOXXON’s pre-clinical data indicate that the efficacy and pharmacokinetic properties of NOX-A12 may lead to a simpler and more effective HSC mobilization procedure compared to current practice.

The results obtained in this Phase I clinical trial will form the basis for the Phase II program to be conducted by mid 2010 in patients with Multiple Myeloma or non-Hodgkin’s Lymphoma
undergoing autologous stem cell transplantation.

About NOX-A12

NOX-A12 mobilizes hematopoietic stem cells from the bone marrow by disrupting the SDF-1 gradient that normally attracts them to their niches. Studies in animal models demonstrate that
treatment with a single dose of Spiegelmer® NOX-A12 significantly mobilizes hematopoietic progenitor cells in a dose dependent manner. NOXXON receives grant support from the
German Federal Ministry of Education and Research (BMBF) for the preclinical program and the first-in-human clinical trial with NOX-A12.

About Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation is considered the treatment of choice for many patients with severe malignant or non-malignant, acquired or congenital disorders of the hematopoietic system or for patients with chemosensitive, radiosensitive or immunosensitive tumors. Better
management of the patients, improved supportive care, increased donor pools and novel
conditioning regimes have extended its use to new patient categories and new disease
conditions.
About Spiegelmers®
Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image
oligonucleotides which are highly selective for their pharmacological target and potent inhibitors
of target function. They combine the benefits of small molecule drugs and biopharmaceuticals.
Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not
hybridize with native nucleic acids. Unlike conventional nucleic acids, Spiegelmers® do not
activate the innate immune response via toll-like receptors and they showed an exceptionally
favorable immunogenicity profile in pre-clinical testing.
About NOXXON
Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the
development of Spiegelmers® for the treatment of inflammatory diseases and hematological
indications. NOXXON is in possession of a broad patent estate and has access to a readily
scalable GMP production. In addition to its in-house programs, NOXXON discovers and
develops Spiegelmers® in collaboration with partners from the pharmaceutical industry, including
Eli Lilly, Hoffmann La-Roche, and Pfizer. The business strategy of NOXXON is to broaden this
range of collaborations through co-development and licensing agreements for the proprietary
clinical and pre-clinical products as well as technology-based multi-target partnerships. Currently
the company has two compounds in clinical development. The declared goal of NOXXON is to
establish its oligonucleotide-based drug discovery platform (Spiegelmers®) as the leading
'scaffold' technology to create new chemical entities with superior properties.
NOXXON’s investors are TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment
Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft (DEWB), Seventure
Partners, Dow Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth- Trends, IBG
Risikokapitalfonds, VC Fonds Berlin, and others.
Website: http://www.noxxon.com
General contact: Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: edelabre@noxxon.com

   
Record changed: 2017-02-15

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for olaptesed pegol (NOX-A12)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpctoc




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px